Migraine Biotech Heads For $86M IPO With Alternative Drug
CoLucid Pharmaceuticals Inc., a biotech developing treatments for migraine headaches, filed a prospectus Monday with the U.S. Securities and Exchange Commission saying it is looking to raise $86 million in an initial...To view the full article, register now.
Already a subscriber? Click here to view full article